Hyperuricemia on Hypertension and Metabolic Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the influence of hyperuricemia treatment compared with placebo on participants with high risk of hypertension and metabolic syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms

NCT04012294

Musculoskeletal Degeneration Inflammation Hyperuricemia

UNKNOWN PHASE3

A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout

NCT00741442

Hyperuricemia

COMPLETED PHASE2

Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

NCT01336686

Hyperuricemia Gout

COMPLETED PHASE2

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

NCT02956278

Chronic Gout Hyperuricemia

COMPLETED PHASE4

Effect of Febuxostat on Blood Pressure

NCT01496469

Hypertension

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Elevated consumption of high fructose corn syrup has lead to an increase of 30% of fructose intake since the last 20 years. Important data supporting this fact can be reflected on incidence and prevalence of Metabolic syndrome and hyperuricemia.

A peculiar effect of fructose intake demonstrated in animal models is the development of elevated uric acid levels; also some studies have found a clear association between hyperuricemia as an important risk factor for hypertension, diabetes mellitus, chronic kidney disease and metabolic syndrome.

Taking into account the existing evidence, our clinical research team presents this protocol as a way to evaluate the effect of uric acid treatment and its relation with Fructose consumption, metabolic syndrome parameters, hyperuricemia and risk of hypertension.

Confirming evidence with clinical basis may be the initial strategy to create primary prevention programs to control this health problems affecting Mexican Population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systolic and Diastolic Blood Pressure Levels Uric Acid Levels Metabolic Syndrome Parameters Hepatic Enzymes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Allopurinol treatment

Group Type ACTIVE_COMPARATOR

Allopurinol

Intervention Type DRUG

daily dosage

Placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

daily dosage

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Allopurinol

daily dosage

Intervention Type DRUG

placebo

daily dosage

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

xanthine oxidase inhibitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adults with blood pressure from 120/80 mmHg and less than 140/90 mmHg
* no pharmacological treatment for blood pressure control

Exclusion Criteria

* hypertension (more than 140/90mmHg)
* Diabetes Mellitus type 1 or 2
* Chronic kidney disease (MDRD less than 60)
* Hepatic Disease
* Malignancy
* Pregnancy
* patient receiving any medication

Minimum Eligible Age

25 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes